-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Allogeneic Donor-Derived T-Cells Transduced With Bivalent Lentiviral Vector (CD19/CD22-BBz) Chimeric Antigen Receptor (CAR) in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Allogeneic Donor-Derived T-Cells Transduced With Bivalent Lentiviral Vector (CD19/CD22-BBz) Chimeric Antigen Receptor (CAR) in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vemircopan in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vemircopan in Lupus Nephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vemircopan in Lupus Nephritis Drug Details: Vemircopan (ALXN-2050) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acetylcysteine Zidrimer in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acetylcysteine Zidrimer in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Acetylcysteine Zidrimer in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))Drug Details:Acetylcysteine zidrimer (OP-101)...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OP-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OP-101 Drug Details OP-101 is under development for the treatment of childhood cerebral andrenoleukodystrophy...
-
Product Insights
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Adrenoleukodystrophy disease is caused by a defect in the gene that tells the body to create lipoproteins. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. The Adrenoleukodystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...